No clinically significant interaction expected.
These drugs should not be coadministered.
Potential interaction which may require a dosage adjustment or close monitoring.
Potential interaction predicted to be of weak intensity. No a priori dosage adjustment is recommended.

Potential increased exposure of the antidepressant
Potential increased exposure of HIV drug
Potential decreased exposure of the antidepressant
Potential decreased exposure of HIV drug
No significant effect

Numbers refer to decreased AUC of the antidepressant as observed in drug-drug interaction studies.

SSRI selective serotonin reuptake inhibitors
SNRI serotonin and norepinephrine reuptake inhibitor
TCA tricyclic antidepressants
TeCA tetracyclic antidepressants

a ECG monitoring is recommended
b The US Prescribing Information recommends that coadministration should be avoided as there are insufficient data to make dosing recommendations. However, the European SPC suggests dolutegravir be dosed at 50 mg twice daily, but recommends alternative combinations to be used where possible in INSTI-resistant patients. (These charts reflect the more cautious option.)